Nature Reviews Cardiology最新文献_第2页

Dual mechanotherapy for the treatment of cardiac fibrosis 双重机械疗法治疗心脏纤维化

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-05-19 DOI: 10.1038/s41569-025-01172-9

Irene Fernández-Ruiz

引用次数: 0

BMAL1 and HIF2α are key regulators of circadian-dependent variations in myocardial injury BMAL1和HIF2α是心肌损伤中昼夜变化的关键调节因子

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-05-12 DOI: 10.1038/s41569-025-01169-4

Karina Huynh

引用次数: 0

Endothelial cell metabolism in cardiovascular physiology and disease 内皮细胞代谢在心血管生理和疾病中的作用

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-05-09 DOI: 10.1038/s41569-025-01162-x

Alessandra Pasut, Eleonora Lama, Amaryllis H. Van Craenenbroeck, Jeffrey Kroon, Peter Carmeliet

{"title":"Endothelial cell metabolism in cardiovascular physiology and disease","authors":"Alessandra Pasut, Eleonora Lama, Amaryllis H. Van Craenenbroeck, Jeffrey Kroon, Peter Carmeliet","doi":"10.1038/s41569-025-01162-x","DOIUrl":"https://doi.org/10.1038/s41569-025-01162-x","url":null,"abstract":"Endothelial cells are multifunctional cells that form the inner layer of blood vessels and have a crucial role in vasoreactivity, angiogenesis, immunomodulation, nutrient uptake and coagulation. Endothelial cells have unique metabolism and are metabolically heterogeneous. The microenvironment and metabolism of endothelial cells contribute to endothelial cell heterogeneity and metabolic specialization. Endothelial cell dysfunction is an early event in the development of several cardiovascular diseases and has been shown, at least to some extent, to be driven by metabolic changes preceding the manifestation of clinical symptoms. Diabetes mellitus, hypertension, obesity and chronic kidney disease are all risk factors for cardiovascular disease. Changes in endothelial cell metabolism induced by these cardiometabolic stressors accelerate the accumulation of dysfunctional endothelial cells in tissues and the development of cardiovascular disease. In this Review, we discuss the diversity of metabolic programmes that control endothelial cell function in the cardiovascular system and how these metabolic programmes are perturbed in different cardiovascular diseases in a disease-specific manner. Finally, we discuss the potential and challenges of targeting endothelial cell metabolism for the treatment of cardiovascular diseases.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"10 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143930876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Social media in modern cardiology: a tool for building community, visibility and impact 现代心脏病学中的社交媒体：建立社区、知名度和影响力的工具

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-05-08 DOI: 10.1038/s41569-025-01164-9

Ritu Thamman, Rafael Vidal-Perez

引用次数: 0

Redefining respiratory sinus arrhythmia as respiratory heart rate variability: an international Expert Recommendation for terminological clarity. 将呼吸性窦性心律失常重新定义为呼吸性心率变异性：术语清晰度的国际专家建议。

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-05-06 DOI: 10.1038/s41569-025-01160-z

Clément Menuet,Alona Ben-Tal,Ambre Linossier,Andrew M Allen,Benedito H Machado,Davi J A Moraes,David G S Farmer,David J Paterson,David Mendelowitz,Edward G Lakatta,Edwin W Taylor,Gareth L Ackland,Irving H Zucker,James P Fisher,James S Schwaber,Julia Shanks,Julian F R Paton,Julie Buron,K Michael Spyer,Kalyanam Shivkumar,Mathias Dutschmann,Michael J Joyner,Neil Herring,Paul Grossman,Robin M McAllen,Rohit Ramchandra,Song T Yao,Thomas Ritz,Alexander V Gourine

{"title":"Redefining respiratory sinus arrhythmia as respiratory heart rate variability: an international Expert Recommendation for terminological clarity.","authors":"Clément Menuet,Alona Ben-Tal,Ambre Linossier,Andrew M Allen,Benedito H Machado,Davi J A Moraes,David G S Farmer,David J Paterson,David Mendelowitz,Edward G Lakatta,Edwin W Taylor,Gareth L Ackland,Irving H Zucker,James P Fisher,James S Schwaber,Julia Shanks,Julian F R Paton,Julie Buron,K Michael Spyer,Kalyanam Shivkumar,Mathias Dutschmann,Michael J Joyner,Neil Herring,Paul Grossman,Robin M McAllen,Rohit Ramchandra,Song T Yao,Thomas Ritz,Alexander V Gourine","doi":"10.1038/s41569-025-01160-z","DOIUrl":"https://doi.org/10.1038/s41569-025-01160-z","url":null,"abstract":"The variation of heart rate in phase with breathing, known as 'respiratory sinus arrhythmia' (RSA), is a physiological phenomenon present in all air-breathing vertebrates. RSA arises from the interaction of several physiological mechanisms but is primarily mediated by rhythmic changes in cardiac parasympathetic (vagal) activity, increasing heart rate during inspiration and decreasing heart rate during expiration. RSA amplitude is an indicator of autonomic and cardiac health; RSA is diminished or absent in common pathological conditions such as chronic heart failure and hypertension. In this Expert Recommendation, we argue that the term 'RSA', although historically important, is semantically inaccurate and carries misleading pathological connotations, contributing to misunderstanding and misinterpretation of the origin and the physiological importance of the phenomenon. We propose replacing 'RSA' with the term 'respiratory heart rate variability' (RespHRV), which avoids pathological connotations and emphasizes the specific respiratory contribution to heart rate variability. We clarify that RespHRV encompasses respiratory-related heart rate variations in both the low-frequency and high-frequency bands traditionally defined in heart rate variability analysis, and that its amplitude should not be misconstrued as a measure of vagal tone. Adopting the proposed term 'RespHRV' is expected to unify understanding and stimulate further experimental and clinical research into the physiological mechanisms and functional importance of this phenomenon.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"51 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cholesterol crystals in the pathogenesis of atherosclerosis. 动脉粥样硬化发病机制中的胆固醇结晶。

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2025-05-01 Epub Date: 2024-11-18 DOI: 10.1038/s41569-024-01100-3

Yvonne Baumer, Jason Irei, William A Boisvert

{"title":"Cholesterol crystals in the pathogenesis of atherosclerosis.","authors":"Yvonne Baumer, Jason Irei, William A Boisvert","doi":"10.1038/s41569-024-01100-3","DOIUrl":"10.1038/s41569-024-01100-3","url":null,"abstract":"The presence of cholesterol crystals (CCs) in tissues was first described more than 100 years ago. CCs have a pathogenic role in various cardiovascular diseases, including myocardial infarction, aortic aneurysm and, most prominently, atherosclerosis. Although the underlying mechanisms and signalling pathways involved in CC formation are incompletely understood, numerous studies have highlighted the existence of CCs at various stages of atheroma progression. In this Review, we summarize the mechanisms underlying CC formation and the role of CCs in cardiovascular disease. In particular, we explore the established links between lipid metabolism across various cell types and the formation of CCs, with a focus on CC occurrence in the vasculature. We also discuss CC-induced inflammation as one of the pathogenic features of CCs in the atheroma. Finally, we summarize the therapeutic strategies aimed at reducing CC-mediated atherosclerotic burden, including approaches to inhibit CC formation in the vasculature or to mitigate the inflammatory response triggered by CCs. Addressing CC formation might emerge as a crucial component in our broader efforts to combat cardiovascular disease.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":"315-332"},"PeriodicalIF":41.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trials and tribulations of cell therapy for heart failure: an update on ongoing trials. 细胞疗法治疗心力衰竭的考验与磨难：正在进行的试验的最新情况。

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2025-05-01 Epub Date: 2024-11-15 DOI: 10.1038/s41569-024-01098-8

Jianyi Jay Zhang, Steven M Pogwizd, Keiichi Fukuda, Wolfram-Hubertus Zimmermann, Chengming Fan, Joshua M Hare, Roberto Bolli, Philippe Menasché

{"title":"Trials and tribulations of cell therapy for heart failure: an update on ongoing trials.","authors":"Jianyi Jay Zhang, Steven M Pogwizd, Keiichi Fukuda, Wolfram-Hubertus Zimmermann, Chengming Fan, Joshua M Hare, Roberto Bolli, Philippe Menasché","doi":"10.1038/s41569-024-01098-8","DOIUrl":"10.1038/s41569-024-01098-8","url":null,"abstract":"Heart failure (HF) remains a leading cause of mortality, responsible for 13% of all deaths worldwide. The prognosis for patients with HF is poor, with only a 50% survival rate within 5 years. A major challenge of ischaemia-driven HF is the loss of cardiomyocytes, compounded by the minimal regenerative capacity of the adult heart. To date, replacement of irreversibly damaged heart muscle can only be achieved by complete heart transplantation. In the past 20 years, cell therapy has emerged and evolved as a promising avenue for cardiac repair and regeneration. During this time, cell therapy for HF has encountered substantial barriers in both preclinical studies and clinical trials but the field continues to progress and evolve from lessons learned from such research. In this Review, we provide an overview of ongoing trials of cell-based and cell product-based therapies for the treatment of HF. Findings from these trials will facilitate the clinical translation of cardiac regenerative and reparative therapies not only by evaluating the safety and efficacy of specific cell-based therapeutics but also by establishing the feasibility of novel or underexplored treatment protocols such as repeated intravenous dosing, personalized patient selection based on pharmacogenomics, systemic versus intramural cell delivery, and epicardial engraftment of engineered tissue products.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":"372-385"},"PeriodicalIF":41.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decongestion in heart failure: medical and device therapies 心力衰竭的去充血：医疗和器械疗法

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-28 DOI: 10.1038/s41569-025-01152-z

Zachary L. Cox, Kevin Damman, Jeffrey M. Testani

引用次数: 0

Sotatercept as add-on therapy for advanced PAH 索替赛普作为晚期多环芳烃的附加治疗

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2025-04-22 DOI: 10.1038/s41569-025-01161-y

Xiulin Köhler

引用次数: 0

Pulsed field ablation non-inferior to cryoablation for paroxysmal AF 脉冲场消融治疗阵发性房颤优于冷冻消融